Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy

Marianna Monfrini, Elisabetta Donzelli, Virginia Rodriguez-Menendez, Elisa Ballarini, Valentina Alda Carozzi, Alessia Chiorazzi, Cristina Meregalli, Annalisa Canta, Norberto Oggioni, Luca Crippa, Federica Avezza, Sara Silvani, Barbara Bonandrini, Marina Figliuzzi, Andrea Remuzzi, Carla Porretta-Serapiglia, Roberto Bianchi, Giuseppe Lauria, Giovanni Tredici, Guido CavalettiArianna Scuteri

Research output: Contribution to journalArticle

Abstract

Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment.

Original languageEnglish
Pages (from-to)75-84
Number of pages10
JournalExperimental Neurology
Volume288
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Islets of Langerhans Transplantation
Diabetic Neuropathies
Peripheral Nervous System Diseases
Mesenchymal Stromal Cells
Mesenchymal Stem Cell Transplantation
Islets of Langerhans
Adult Stem Cells
Type 1 Diabetes Mellitus
Therapeutics
Insulin
Population
Painful Neuropathy

Keywords

  • Diabetes
  • Diabetic neuropathy
  • Mesenchymal stem cell
  • Pancreatic islet transplantation

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Monfrini, M., Donzelli, E., Rodriguez-Menendez, V., Ballarini, E., Carozzi, V. A., Chiorazzi, A., ... Scuteri, A. (2017). Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. Experimental Neurology, 288, 75-84. https://doi.org/10.1016/j.expneurol.2016.11.006

Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. / Monfrini, Marianna; Donzelli, Elisabetta; Rodriguez-Menendez, Virginia; Ballarini, Elisa; Carozzi, Valentina Alda; Chiorazzi, Alessia; Meregalli, Cristina; Canta, Annalisa; Oggioni, Norberto; Crippa, Luca; Avezza, Federica; Silvani, Sara; Bonandrini, Barbara; Figliuzzi, Marina; Remuzzi, Andrea; Porretta-Serapiglia, Carla; Bianchi, Roberto; Lauria, Giuseppe; Tredici, Giovanni; Cavaletti, Guido; Scuteri, Arianna.

In: Experimental Neurology, Vol. 288, 01.02.2017, p. 75-84.

Research output: Contribution to journalArticle

Monfrini, M, Donzelli, E, Rodriguez-Menendez, V, Ballarini, E, Carozzi, VA, Chiorazzi, A, Meregalli, C, Canta, A, Oggioni, N, Crippa, L, Avezza, F, Silvani, S, Bonandrini, B, Figliuzzi, M, Remuzzi, A, Porretta-Serapiglia, C, Bianchi, R, Lauria, G, Tredici, G, Cavaletti, G & Scuteri, A 2017, 'Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy', Experimental Neurology, vol. 288, pp. 75-84. https://doi.org/10.1016/j.expneurol.2016.11.006
Monfrini M, Donzelli E, Rodriguez-Menendez V, Ballarini E, Carozzi VA, Chiorazzi A et al. Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. Experimental Neurology. 2017 Feb 1;288:75-84. https://doi.org/10.1016/j.expneurol.2016.11.006
Monfrini, Marianna ; Donzelli, Elisabetta ; Rodriguez-Menendez, Virginia ; Ballarini, Elisa ; Carozzi, Valentina Alda ; Chiorazzi, Alessia ; Meregalli, Cristina ; Canta, Annalisa ; Oggioni, Norberto ; Crippa, Luca ; Avezza, Federica ; Silvani, Sara ; Bonandrini, Barbara ; Figliuzzi, Marina ; Remuzzi, Andrea ; Porretta-Serapiglia, Carla ; Bianchi, Roberto ; Lauria, Giuseppe ; Tredici, Giovanni ; Cavaletti, Guido ; Scuteri, Arianna. / Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. In: Experimental Neurology. 2017 ; Vol. 288. pp. 75-84.
@article{8158884f4eeb404dada9706c7c9bf7b9,
title = "Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy",
abstract = "Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment.",
keywords = "Diabetes, Diabetic neuropathy, Mesenchymal stem cell, Pancreatic islet transplantation",
author = "Marianna Monfrini and Elisabetta Donzelli and Virginia Rodriguez-Menendez and Elisa Ballarini and Carozzi, {Valentina Alda} and Alessia Chiorazzi and Cristina Meregalli and Annalisa Canta and Norberto Oggioni and Luca Crippa and Federica Avezza and Sara Silvani and Barbara Bonandrini and Marina Figliuzzi and Andrea Remuzzi and Carla Porretta-Serapiglia and Roberto Bianchi and Giuseppe Lauria and Giovanni Tredici and Guido Cavaletti and Arianna Scuteri",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.expneurol.2016.11.006",
language = "English",
volume = "288",
pages = "75--84",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy

AU - Monfrini, Marianna

AU - Donzelli, Elisabetta

AU - Rodriguez-Menendez, Virginia

AU - Ballarini, Elisa

AU - Carozzi, Valentina Alda

AU - Chiorazzi, Alessia

AU - Meregalli, Cristina

AU - Canta, Annalisa

AU - Oggioni, Norberto

AU - Crippa, Luca

AU - Avezza, Federica

AU - Silvani, Sara

AU - Bonandrini, Barbara

AU - Figliuzzi, Marina

AU - Remuzzi, Andrea

AU - Porretta-Serapiglia, Carla

AU - Bianchi, Roberto

AU - Lauria, Giuseppe

AU - Tredici, Giovanni

AU - Cavaletti, Guido

AU - Scuteri, Arianna

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment.

AB - Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment.

KW - Diabetes

KW - Diabetic neuropathy

KW - Mesenchymal stem cell

KW - Pancreatic islet transplantation

UR - http://www.scopus.com/inward/record.url?scp=84995752904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995752904&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2016.11.006

DO - 10.1016/j.expneurol.2016.11.006

M3 - Article

AN - SCOPUS:84995752904

VL - 288

SP - 75

EP - 84

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -